Amendments To The Claims

74. (Original) A method of treating B cell lymphoma in a patient in need of such treatment which method includes the administration of anti-IL10 antibody and at least one B cell depleting antibody.

75. (Previously presented) The method of Claim 74 wherein said B cell depleting antibody binds to a B cell antigen from the group consisting of CD19, CD20, CD22, CD23, CD27, CD37, CD53, CD72, CD73, CD74, CDω78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86.

76. (Original) A method of treating B cell lymphoma in a patient in need of such treatment which method comprises the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 or anti-CD22 antibody.

77. (Original) A method of treating B cell lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 antibody.

78. (Original) A method of treating non-Hodgkin's lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting antibody.

79. (Original) A method of treating non-Hodgkin's lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 antibody.

81. (Previously presented) The method of Claim 77 wherein said antibody is RITUXAN® (rituximab).

82. (Previously presented) The method of Claim 79 wherein said antibody is RITUXAN® (rituximab).

83. (Original) A combination therapy for treating B cell lymphoma in a patient comprising the administration of a therapeutically effective amount of an anti-IL10 antibody, a B cell depleting anti-CD20 antibody and chemotherapy.

84. (Previously presented) The method of Claim 83 wherein said anti CD20 antibody is RITUXAN® (rituximab).

85. (Original) The method of Claim 83 wherein said patient has relapsed following previous treatment with a B cell depleting antibody.

86. (Previously presented) The method of Claim 85 wherein said antibody is RITUXAN® (rituximab).

87. (Previously presented) The method of Claim 75 wherein the B cell depleting antibody binds CD20.

89. (Previously presented) The method of Claim 87 wherein said antibody is a chimeric anti-CD20 antibody.

90. (Previously presented) The method of Claim 89 wherein said chimeric anti-CD20 antibody is RITUXAN® (rituximab).

91. (Previously presented) The method of Claim 74 wherein said treating is combined with chemotherapy.

92. (Previously presented) The method of Claim 74 wherein said B cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL and Waldenstrom's Macroglobulinemia.

93. (Previously presented) The method of Claim 74 wherein said antibodies are administered by intravenous, intramuscular, intratumeoral or intraperitoneal administration.

94. (Previously presented) The method of Claim 91 wherein said chemotherapy is selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA (with or without subsequent G-CSF treatment), VAD, M&P, C-Weekly, ABCM, MOPP, DHAP, daunorubicin, doxorubicin, methotrexate, and cisplatin.

95. (Previously presented) The method of Claim 74 wherein either or both of said antibodies are human, humanized or chimeric antibodies.

96. (Previously presented) The method of Claim 74 wherein the dosage of said antibodies range from 0.01 to 1000 mg/kg body weight.

97. (New) A method of treating B cell lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 antibody, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8.

98. (New) The method of claim 97, wherein the anti-CD20 antibody further comprises human constant regions.

99. (New) The method of claim 79, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8.

100. (New) The method of claim 99, wherein the anti-CD20 antibody further comprises human constant regions.

101. (New) The method of claim 83, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8.

102. (New) The method of claim 101, wherein the anti-CD20 antibody further comprises human constant regions.